logo
Share SHARE
FONT-SIZE Plus   Neg

Repros Therapeutics To Meet With FDA To Discuss Phase 3 Study Design Of Androxal

Repros Therapeutics Inc.(RPRX) Monday said the FDA has scheduled a meeting in May to discuss the design of pivotal Phase 3 efficacy studies for Androxal, as well as the components of the overall drug development program required for NDA submission.

Androxal is an oral therapy intended for the treatment of secondary hypogonadism. Unlike the hormone replacement therapies currently approved to treat this disorder, Androxal restores testicular function resulting in normal synthesis of testosterone and continued spermatogenesis.

Repros said studies using approved testosterone replacement therapies as efficacy and safety comparators have shown the approved treatments result in suppression of important pituitary hormones that drive testicular function down to castration levels in a significant number of men.

Joseph Podolski, president and CEO of The Woodlands, Texas-based company, said," Our goal is to work with the FDA to provide a complete drug dossier for Androxal that exhibits the products' clinical benefit and safety. Depending on FDA comments, we believe we can submit the NDA early in 2014."

RPRX closed Monday's regular trade at $4.35, down $0.15 or 3.33%, on the Nasdaq. In the after-hours, the stock gained $0.01 or 0.23%. Over the past year, the stock traded in a range of $3.34 - $6.85.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of Infineon Technologies AG were losing around 4 percent in German trading after the manufacturer of semiconductors and system solutions reduced its revenue growth forecast for fiscal 2016. This was despite a surge in second-quarter profit with strong revenues. For the third quarter, the company projects revenue growth sequentially. Halliburton Company (HAL) reported a loss from continuing operations of $2.4 billion, or $2.81 per share, in the first quarter of 2016, compared to a loss of $639 million or $0.75 per share, previous year. Halliburton recorded company-wide charges related primarily to asset impairments and severance... Pfizer Inc. (PFE) reported a profit for first-quarter 2016 that increased 27 percent from last year. Both earnings per share and revenue for the quarter beat analysts' expectations. The company raised its fiscal year 2016 guidance to reflect the strong operational performance.
comments powered by Disqus
Follow RTT